CR2-mediated targeting of complement inhibitors: Bench-to-bedside using a novel strategy for site-specific complement modulation

Advances in Experimental Medicine and Biology

Volumn 734, Issue , 2013, Pages 137-154

  Holers, V Michael ^a   Rohrer, Bärbel ^b,c   Tomlinson, Stephen ^b,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT INHIBITOR; COMPLEMENT RECEPTOR; COMPLEMENT RECEPTOR CR2; CR2 CD59 FUSION PROTEIN; CR2 CRYY FUSION PROTEIN; CR2 DECAY ACCELERATING FACTOR FUSION PROTEIN; HYBRID PROTEIN; MIROCOCEPT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C5; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY CRRY FUSION PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY DECAY ACCELERATING FACTOR FUSION PROTEIN; UNCLASSIFIED DRUG; CR2 PROTEIN; REGULATOR PROTEIN; SELECTIN (GLYCOPROTEIN);

ARTHRITIS; AUTOIMMUNE DISEASE; BINDING AFFINITY; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; CONFERENCE PAPER; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; GENETIC ASSOCIATION; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MOLECULARLY TARGETED THERAPY; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOGENESIS; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; STRUCTURE ACTIVITY RELATION; TISSUE INJURY; VALIDATION PROCESS; AGE RELATED MACULAR DEGENERATION; BINDING SITE; COMPLEMENT DISORDER; DRUG POTENCY; INFECTION PREVENTION; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; TRANSLATIONAL RESEARCH; TURNOVER RATE;

EID: 84934442096     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-4118-2_9     Document Type: Conference Paper

References (106)

1. Asokan R, Hua J, Young KA, Gould HJ, Hannan JP, Kraus DM, Szakonyi G, Grundy GJ, Chen XS, Crow MK, Holers VM (2006) Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for interferon-alpha: a potential role in systemic lupus erythematosus. J Immunol 177:383-3944
2. Atkinson C, Song H, Lu B, Qiao F, Burns TA, Holers VM, Tsokos GC, Tomlinson S (2005) Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest 115:2444-24533
3. Atkinson C, Zhu H, Qiao F, Varela JC, Yu J, Song H, Kindy MS, Tomlinson S (2006) Complement-dependent P-selectin expression and injury following ischemic stroke. J Immunol 177:7266-72744
4. Atkinson C, Qiao H, Song H, Gilkeson GS, Tomlinson S (2008) Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol 180: 1231-12388
5. Atkinson C, He S, Morris K, Qiao F, Casey S, Goddard M, Tomlinson S (2010) Targeted complement inhibitors protect against posttransplant cardiac ischemia and reperfusion injury and reveal an important role for the alternative pathway of complement activation. J Immunol 185:7007-70133
6. Aubry JP, Pochon S, Graber P, Jansen KU, Bonnefoy JY (1992) CD21 is a ligand for CD23 and regulates IgE production. Nature 358:505-5077
7. Banda NK, Levitt B, Glogowska M, Thurman JM, Takahashi K, Stahl GL, Tomlinson S, Arend WP, Holers VM (2009) Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J Immunol 183:5928-59377
8. Bao L, Haas M, Kraus DM, Hack BK, Rakstang JK, Holers VM, Quigg RJ (2003) Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice. J Am Soc Nephrol 14:670-6799
9. Bora NS, Kaliappan S, Jha P, Xu Q, Sohn JH, Dhaulakhandi DB, Kaplan HJ, Bora PS (2006) Complement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: role of factor B and factor H. J Immunol 177:1872-18788
10. Bora NS, Kaliappan S, Jha P, Xu Q, Sivasantar B, Harris CL, Morgan BP, Bora PS (2007) CD59, a complement regulatory protein, controls choroidal neovascularization in a mouse model of wet-type age-related macular degeneration. J Immunol 178:1783-17900
11. Bora NS, Jha P, Lyzogubov VV, Kaliappan S, Liu J, Tytarenko RJ, Fraser DA, Morgan BP, Bora PS (2010) Recombinant membrane-targeted form of CD59 inhibits the growth of choroidal neovascular complex in mice. J Biol Chem 285:33826-338333
12. Botto M, Walport MJ (2002) C1q, autoimmunity and apoptosis. Immunobiology 205:395-4066
13. Brown EJ (1991) Complement receptors and phagocytosis. Curr Opin Immunol 3:76-822
14. Carel JC, Frazier B, Ley TJ, Holers VM (1989) Analysis of epitope expression and the functional repertoire of recombinant complement receptor 2 (CR2/CD21) in mouse and human cells. J Immunol 143:923-9300
15. Carel JC, Myones BL, Frazier B, Holers VM (1990) Structural requirements for C3d, g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection. J Biol Chem 265:12293-122999
16. Carroll MC (1998a) CD21/CD35 in B cell activation. Semin Immunol 10(4):279-2866
17. Carroll MC (1998b) The role of complement and complement receptors in the induction and regulation of immunity. Annu Rev Immunol 16:545-5688
18. Carroll MC (2000) The role of complement in B cell activation and tolerance. Adv Immunol 74:61-888
19. Carter RH, Spycher MO, Ng YC, Hoffman R, Fearon DT (1998) Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes. J Immunol 141:457-4633
20. Cashman SM, Ramo K, Kumar-Singh R (2011) A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration. PLoS One 6:e190788
21. Cicardi M, Zanichelli A (2012) Replacement therapy with C1esterase inhibitors for hereditary angioedema. Drugs Today 46:867-8744
22. Davies KA, Peters AM, Beynon HLC, Walport MJ (1992) Immune complex processing in patients with systemic lupus erythematosus. J Clin Invest 90:2075-20833
23. Davies KA, Schifferli JA, Walport MJ (1994) Complement Deficiency and immune complex disease. Springer Semin Immunopathol 15:397-4166
24. Donoso LA, Kim EE, Frost A, Callahan A, Hageman G (2006) The role of in flammation in the pathogenesis of agerelated macular degeneration. Surv Ophthalmol 51:137-1522
25. Elvington M, Huang Y, Morgan BP, Qiao F, van Rooijen N, Atkinson C, Tomlinson S (2012) A targeted complementdependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood Mar 22 [Epub ahead of print]
26. Esparza I, Becherer JD, Alsenz J, De la Hera A, Lao Z, Tsoukas CD, Lambris JD (1991) Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor, CD21). Eur J Immunol 21:2829-28388
27. Fearon DT, Locksley RM (1996) The instructive role of innate immunity in the acquired immune response. Science 272:50-544
28. Fraser DA, Harris CL, Williams AS, Mizuno M, Gallagher S, Smith RA, Morgan BP (2003) Generation of a recombinant, membrane-targeted form of the complement regulator CD59: activity in vitro and in vivo. J Biol Chem 278:48921-489277
29. Fridkis-Hareli M, Storek M, Maszaroff I, Risitano AM, Lundberg AS, Horvath CJ, Holers VM (2011) Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood 118:4705-47133
30. Gadjeva M, Takahashi K, Thiel S (2004) Mannan-binding lectin - a soluble pattern recognition molecule. Mol Immunol 41:113-1211
31. Gehrs KM, Anderson DH, Johnson LV, Hageman GS (2006) Age-related macular degeneration-emerging pathogenetic and therapeutic concepts. Ann Med 38:450-4711
32. Gorin MB (2005) A new vision for age-related macular degeneration. Eur J Hum Genet 13:793-7944
33. Halstead SK, Humphreys PD, Goodfellow JA, Wagner ER, Smith ER, Willison HJ (2005) Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome. Ann Neurol 58:203-2100
34. Harris CL, Fraser DA, Morgan BP (2002) Tailoring anti-complement therapeutics. Biochem Soc Trans 30:1019-10266
35. Hart ML, Ceonzo KA, Shaffer LA, Takahashi K, Rother RP, Reenstra WR, Buras JA, Stahl GL (2005) Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q. J Immunol 174:6373-63800
36. He C, Imai M, Song H, Quigg RJ, Tomlinson S (2005) Complement inhibitors targeted to the proximal tubule prevent injury in experimental nephrotic syndrome and demonstrate a key role for C5b-9. J Immunol 174:5750-57577
37. He S, Atkinson C, Evans Z, Ellett JD, Southwood M, Elvington A, Chavin KD, Tomlinson S (2009a) A role for complement in the enhanced susceptibility of steatotic livers to ischemia and reperfusion injury. J Immunol 183: 4764-47722
38. He S, Atkinson C, Qiao F, Cianflone K, Chen C, Tomlinson S (2009b) A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice. J Clin Invest 119:2304-23166
39. Holers VM (2001) Complement. In: Rich R (ed) Principles and practices of clinical immunology. Mosby, St. Louis, MO, pp 21.1-21.88
40. Holers VM (2005) Complement receptors and the shaping of the natural antibody repertoire. Springer Semin Immunopathol 26:405-4233
41. Holers VM (2008) The spectrum of complement alternative pathway-mediated diseases. Immunol Rev 223:300-3166
42. Holers VM, Boackle SA (2004) Complement receptor 2 and autoimmunity. Curr Dir Autoimmun 7:33-488
43. Holers VM, Carroll MC (2005) Innate autoimmunity. Adv Immunol 86:137-1577
44. Hourcade D, Holers VM, Atkinson JP (1989) The regulators of complement activation (RCA) gene cluster. Adv Immunol 45:381-4166
45. Huang J, Kim LJ, Mealey R, Marsh HC Jr, Zhang Y, Tenner AJ, Connelly ES Jr, Pinsky DJ (1999) Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science 285:595-5999
46. Huang Y, Qiao F, Atkinson C, Holers VM, Tomlinson S (2008) A novel targeted inhibitor of the alternative pathway and its therapeutic use in ischemia/reperfusion injury. J Immunol 181:8068-80766
47. Hylton DJ, Hoffman SM, van Rooijen N, Tomlinson S, Fleming SD (2011) Macrophage-produced IL-12p70 mediates hemorrhage-induced damage in a complement-dependent manner. Shock 35:134-1400
48. Iida K, Nadler L, Nussenzweig V (1983) Identi fication of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody. J Exp Med 158:1021-10333
49. Imai M, Ohta R, Varela JC, Song H, Tomlinson S (2007) Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement. Cancer Res 67:9535-95411
50. Jha P, Bora PS, Bora NS (2007) The role of the complement system in ocular diseases including uveitis and macular degeneration. Mol Immunol 44:3901-39088
51. Jordan JE, Montalto MC, Stahl GL (2001) Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation 104:1413-14188
52. Kalli KR, Ahearn JM, Fearon DT (1991) Interaction of iC3b with recombinant isotypic and chimeric forms of CR2. J Immunol 147:590-5944
53. Kaya Z, Afanasyeva M, Wang Y, Dohmen KM, Schlichting J, Tretter T, Fairweather D, Holers VM, Rose N (2001) Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat Immunol 2:739-7455
54. Khan MA, Jiang X, Dhillon G, Beilke J, Holers VM, Atkinson C, Tomlinson S, Nicolls MR (2011) CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Circ Res 109:1290-13011
55. Khandhadia S, Lotery A (2010) Oxidation and age-related macular degeneration: insights from molecular biology. Expert Rev Mol Med 12:e344
56. Lachmann PJ, Hughes-Jones NC (1984) Initiation of complement activation. Springer Semin Immunopathol 7:143-1622
57. Lambris JD, Sahu A (2001) Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol Rev 180:35-488
58. Linton SM, Williams AS, Dodd I, Smith RA, Williams BD, Morgan BP (2012) Therapeutic efficacy of a novel membrane- targeted complement regulator in antigen-induced arthritis in the rat. Arthritis Rheum 43:2590-25977
59. Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atkinson JP (1996) Control of the complement system. Adv Immunol 61:201-2833
60. Lowell CA, Klickstein LB, Carter RH, Mitchell JA, Fearon DT, Ahearn JM (1989) Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2. J Exp Med 170:1931-19466
61. Molina H (2002) The murine complement regulator Crry: new insights into the immunobiology of complement regulation. Cell Mol Life Sci 59:220-2299
62. Molina H, Wong W, Kinoshita T, Brenner C, Foley S, Holers VM (1992) Distinct receptor and regulatory properties of recombinant mouse Complement Receptor 1 (CR1) and Crry, the two genetic homologs of human CR1. J Exp Med 175:121-1299
63. Molina H, Perkins SJ, Guthridge J, Gorka J, Kinoshita T, Holers VM (1995) Characterization of a complement receptor 2 (CD2, CD21) ligand binding site for C3: an initial model of ligand interaction with two linked SCR modules. J Immunol 154:5426-54355
64. Morgan BP, Berg CW, Harris CL (2005) "Homologous restriction" in complement lysis: roles of membrane complement regulators. Xenotransplantation 12:258-2655
65. Muller-Eberhard HJ (1988) Molecular organization and function of the complement system. Annu Rev Biochem 57:321-3477
66. Mulligan MS, Warner RL, Rittershaus CW, Thomas LJ, Ryan US, Foreman KE, Crouch LD, Till GO, Ward PA (1999) Endothelial targeting and enhanced antiinflammatory effects of complement inhibitors possessing Sialyl Lewis x moieties. J Immunol 162:4952-49599
67. Nozaki M, Raisler BJ, Sakuria E, Sarma JV, Barnum SR, Lambris JD, Chen Y, Zhang K, Ambati BK, Baf fi JZ, Ambati J (2006) Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci 103:2328-23333
68. Pascariello C, Selleri C, Del Vecchio L, Horvath CJ, Holers VM, Risitano AM (2012) A candidate complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria: preclinical data with TT30, a therapeutic that selectively blocks the complement alternative pathway. Blood May 10 [Epub ahead of print]
69. Patel H, Smith RAG, Sacks SH, Zhou W (2006) Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage. J Am Soc Nephrol 17:1102-11111
70. Qiao F, Atkinson C, Song H, Pannu R, Singh I, Tomlinson S (2006) Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am J Pathol 169:1039-10477
71. Qiao F, Atkinson C, Kindy MS, Shunmugavel A, Morgan BP, Song H, Tomlinson S (2010) The alternative and terminal pathways of complement mediate post-traumatic spinal cord in flammation and injury. Am J Pathol 177:3061-30700
72. Qing X, Redecha PB, Burneister MA, Tomlinson S, D'Agati VD, Davisson RL, Salmon JE (2011) Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int 79:331-3399
73. Reid KBM, Turner MW (1994) Mammalian lectins in activation and clearance mechanisms involving the complement system. Springer Semin Immunopathol 15:307-3255
74. Renner BR, Ferreira VP, Cortes C, Goldberg R, Ljubanovic D, Pangburn MK, Pickering MC, Tomlinson S, Holland-Neidermyer A, Strassheim D, Holers VM, Thurman JM (2011) Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury. Kidney Int 80:165-1733
75. Ricklin D, Lambris JD (2007) Complement-targeted therapeutics. Nat Biotechnol 25:1265-12755
76. Risitano AM, Notaro R, Marando L, Serio B, Ranaldi D, Seneca E, Ricci P, Alfinito F, Camera A, Gianfaldoni G, Amendola A, Boschetti C, Di Bona E, Fratellanza G, Barbano F, Rodeghiero F, Zanella A, Iori AP, Selleri C, Luzzatto L, Rotoli B (2009) Complement fraction 3 binding on erythrocytes as an additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 113:4094-41000
77. Rohrer B, Long Q, Coughlin B, Wilson RB, Huang Y, Qiao F, Tang PH, Kunchithapautham K, Gilkeson GS, Tomlinson S (2009) A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of agerelated macular degeneration. Invest Opthalmol Vis Sci 50:3056-30644
78. Rohrer B, Coughlin B, Kunchithapautham K, Long Q, Tomlinson S, Takahashi K, Holers VM (2011) The alternative pathway is required, but not alone suf ficient, for retinal pathology in mouse laser-induced choroidal neovascularization. Mol Immunol 48:e1-e88
79. Rohrer B, Coughlin B, Holers VM (2012) Systemic human CR2-targeted complement alternative pathway inhibitor treatment ameliorates mouse laser-induced choroidal neovascularization. J Ocul Pharmacol Ther Feb 6 [Epub ahead of print]
80. Rosse WF, Nishimura J (2003) Clinical manifestations of paroxysmal nocturnal hemoglobinuria: present state and future problems. Int J Hematol 77:113-1200
81. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25:1256-12644
82. Runza VL, Schwaeble W, Mannel DN (2008) Ficolins: novel pattern recognition molecules of the innate immune response. Immunobiology 213:297-3066
83. Sarrias MR, Franchini S, Canziani G, Argyropoulos E, Moore WT, Sahu A, Lambris JD (2001) Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220. J Immunol 167:1490-14999
84. Schepp-Berglind J, Atkinson C, Elvington M, Qiao F, Mannon P, Tomlinson S (2012) Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitis. J Immunol Jun 15, 188(12):6309-63188
85. Sekine H, Kinser TT, Qiao F, Martinez E, Paulling E, Ruiz P, Gilkeson GS, Tomlinson S (2011a) The bene fi t of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum 63:1076-10855
86. Sekine H, Ruiz P, Gilkeson GS, Tomlinson S (2011b) The dual role of complement in the progression of renal disease in NZB/W F(1) mice and alternative pathway inhibition. Mol Immunol 49:317-3233
87. Smith RA (2002) Targeting anticomplement agents. Biochem Soc Trans 30:1037-10411
88. Song H, He C, Knaak C, Guthridge JM, Holers VM, Tomlinson S (2003) Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest 111:1875-18855
89. Song H, Qiao F, Atkinson C, Holers VM, Tomlinson S (2007) A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis. J Immunol 179:7860-78699
90. Souza DG, Esser D, Bradford R, Vieira AT, Teixeira MM (2005) APT070 (Mirococept), a membrane-localized complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury. Br J Pharmacol 145:1027-10344
91. Spitzer D, Unsinger J, Mao D, Wu X, Molina H, Atkinson JP (2005) In vivo correction of complement regulatory protein Deficiency with an inhibitor of targeting the red blood cell membrane. J Immunol 175:7763-77700
92. Stahl GL, Xu Y, Hao L, Miller M, Buras JA, Fung M, Zhao H (2003) Role for the alternative complement pathway in ischemia/reperfusion injury. Am J Pathol 162:449-4555
93. Strey CW, Markiewski M, Matellos D, Tudoran R, Spruce LA, Greenbaum LE, Lambris JD (2003) The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med 198:913-9233
94. Sun S, Guo Y, Zhao G, Zhou X, Li J, Hu J, Yu H, Chen Y, Song H, Qiao F, Xu G, Yang F, Wu Y, Tomlinson S, Duan Z, Zhou Y (2011a) Complement and the alternative pathway play an important role in LPS/D-GalN-induced fulminant hepatic failure. PLoS One 6:e268388
95. Sun S, Wang H, Zhao G, An Y, Guo Y, Du L, Song H, Qiao F, Yu H, Wu X, Atkinson C, Jiang S, Tomlinson S, Zhou Y (2011b) Complement inhibition alleviates paraquat-induced acute lung injury. Am J Respir Cell Mol Biol 45:834-8422
96. Takeda K, Thurman JM, Tomlinson S, Okamoto M, Shiraishi Y, Ferreira VP, Cortes C, Pangburn MK, Holers VM, Gelfand EW (2012) The critical role of complement alternative pathway regulator factor H in allergen-induced airway hyperresponsiveness and in flammation. J Immunol 188:661-6677
97. Thurman JM, Holers VM (2006) The central role of the alternative complement pathway in human disease. J Immunol 176:1305-13100
98. Tsokos GC (2012) Systemic lupus erythematosus. N Engl J Med 365:2110-21211
99. van den Elsen JM, Isenman DE (2011) A crystal structure of the complex between human complement receptor 2 and its ligand C3d. Science 332:608-6111
100. Wang Q, Rozelle AL, Lepus CM, Scanzello CR, Song JJ, Larsen DM, Crish JF, Bebek G, Ritter SY, Lindstrom TM, Hwang I, Wong HH, Punzi L, Encarnacion A, Shamloo M, Goodman SB, Wyss-Coray T, Goldring SR, Banda NK, Thurman JM, Gobezie R, Crow MK, Holers VM, Lee DM, Robinson WH (2011) Identi fication of a central role for complement in osteoarthritis. Nat Med 17:1674-16799
101. Weis JJ, Toothaker LE, Smith JA, Weis JH, Fearon DT (1988) Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins. J Exp Med 167:1047-10666
102. Wetsel RA (1995) Structure, function and cellular expression of complement anaphylatoxin receptors. Curr Opin Immunol 7:48-533
103. Wu YQ, Qu H, Sfyroera G, Tzekou A, Kay BK, Nilsson B, Ekdahl KN, Ricklin D, Lambris JD (2011) Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine. J Immunol 186:4269-42777
104. Zhang H-F, Yu J, Bajwa E, Morrison SL, Tomlinson S (1999) Targeting of functional antibody-CD59 fusion proteins to a cell surface. J Clin Invest 103:55-611
105. Zhang H, Lu S, Morrison SL, Tomlinson S (2001) Targeting of functional antibody-decay-accelerating factor fusion proteins to a cell surface. J Biol Chem 276:27270-272755
106. Zipfel PF, Skerka C, Hellwage J, Jokiranta ST, Meri S, Brade V, Kraiczy P, Noris M, Remuzzi G (2002) Factor H family proteins: on complement, microbes and human diseases. Biochem Soc Trans 30:971-9788